BACKGROUND: The FLT3 gene is frequently mutated in acute myeloid leukemia (AML), either by an internal tandem duplication (ITD) of the juxtamembrane domain or by activating point mutations in the second tyrosine kinase domain (ATKD). Only a few investigations have focused on the prognostic significance of FLT3 alterations in AML among the elderly, yielding conflicting results. In the present study, the frequency and clinical relevance of FLT3 abnormalities were ascertained in a cohort of elderly AML patients. PATIENTS AND METHODS: A total of 109 AMLs, occurring in patients above the age of 60 yr (median 71.5), were investigated. DNA was extracted from fresh bone marrow cells or from cells in fixative and investigated for the presence of ITD of exons 14 and 15 and the ATKD D835 in exon 20. RESULTS: ITDs and ATKDs were identified in 20 (18%) and 11 (10%) of the cases, respectively. Three cases displayed both an ITD and an ATKD. FLT3 abnormalities were associated with leukocytosis (ITD P < 0.01; ATKD P = 0.069), and the monocytic FAB subtypes M4 and M5 [ITD (P < 0.05), ATKD (P = 0.05)], and ITD and ATKD were significantly (P < 0.05) more common in cases with a normal karyotype. There was no correlation between the presence of FLT3 abnormalities and complete remission rates or overall survival. CONCLUSION: A correlation was observed between FLT3 abnormalities and leukocytosis, a normal karyotype, and the M4/M5 subtypes of leukemia. However, no clear-cut prognostic impact of FLT3 abnormalities was identified in elderly AML patients. Copyright Blackwell Munksgaard 2004.
BACKGROUND: The FLT3 gene is frequently mutated in acute myeloid leukemia (AML), either by an internal tandem duplication (ITD) of the juxtamembrane domain or by activating point mutations in the second tyrosine kinase domain (ATKD). Only a few investigations have focused on the prognostic significance of FLT3 alterations in AML among the elderly, yielding conflicting results. In the present study, the frequency and clinical relevance of FLT3 abnormalities were ascertained in a cohort of elderly AMLpatients. PATIENTS AND METHODS: A total of 109 AMLs, occurring in patients above the age of 60 yr (median 71.5), were investigated. DNA was extracted from fresh bone marrow cells or from cells in fixative and investigated for the presence of ITD of exons 14 and 15 and the ATKD D835 in exon 20. RESULTS: ITDs and ATKDs were identified in 20 (18%) and 11 (10%) of the cases, respectively. Three cases displayed both an ITD and an ATKD. FLT3 abnormalities were associated with leukocytosis (ITD P < 0.01; ATKD P = 0.069), and the monocytic FAB subtypes M4 and M5 [ITD (P < 0.05), ATKD (P = 0.05)], and ITD and ATKD were significantly (P < 0.05) more common in cases with a normal karyotype. There was no correlation between the presence of FLT3 abnormalities and complete remission rates or overall survival. CONCLUSION: A correlation was observed between FLT3 abnormalities and leukocytosis, a normal karyotype, and the M4/M5 subtypes of leukemia. However, no clear-cut prognostic impact of FLT3 abnormalities was identified in elderly AMLpatients. Copyright Blackwell Munksgaard 2004.
Authors: Harshabad Singh; Salma Asali; Lillian L Werner; Daniel J DeAngelo; Karen K Ballen; Philip C Amrein; Martha Wadleigh; Ilene Galinsky; Donna S Neuberg; Edward A Fox; Richard M Stone; Eyal C Attar Journal: Leuk Res Date: 2011-06-21 Impact factor: 3.156
Authors: Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Courtney D DiNardo; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Carlos Bueso-Ramos; Elias Jabbour; Farhad Ravandi; Jorge Cortes; Hagop Kantarjian Journal: Am J Hematol Date: 2016-02 Impact factor: 10.047
Authors: Susan P Whitman; Amy S Ruppert; Michael D Radmacher; Krzysztof Mrózek; Peter Paschka; Christian Langer; Claudia D Baldus; Jing Wen; Frederick Racke; Bayard L Powell; Jonathan E Kolitz; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2007-10-16 Impact factor: 22.113
Authors: Volker Wacheck; Michael Lahn; Gemma Dickinson; Wolfgang Füreder; Renata Meyer; Susanne Herndlhofer; Thorsten Füreder; Georg Dorfner; Sada Pillay; Valérie André; Timothy P Burkholder; Jacqueline K Akunda; Leann Flye-Blakemore; Dirk Van Bockstaele; Richard F Schlenk; Wolfgang R Sperr; Peter Valent Journal: Cancer Manag Res Date: 2011-05-10 Impact factor: 3.989
Authors: Susanne Warrenfeltz; Stephen Pavlik; Susmita Datta; Eileen T Kraemer; Benedict Benigno; John F McDonald Journal: Mol Cancer Date: 2004-10-07 Impact factor: 27.401
Authors: Ghaleb Elyamany; Mohammad Awad; Kamal Fadalla; Mohamed Albalawi; Mohammad Al Shahrani; Abdulaziz Al Abdulaaly Journal: Adv Hematol Date: 2014-02-20